Completing the $7.2 billion buyout of AspenTech "marks a key milestone in the final phase of Emerson's portfolio ...

The completed campus near Salt Lake City will have more than 1 million sq ft of data centers with a combined 175-MW capacity.

Amid a broad-market correction, digital asset investors have turned to tokenized U.S. Treasury products, pushing their ...

A statue of a football hero and a tramway set to transform a town which once won "grumpiest town" in the West Midlands and ...

The company’s Phase IIb trial found the therapy, N6LS, was able to maintain viral loads below a detectable threshold.

Phase 3 AURORA trial of Descartes-08 in myasthenia gravis on track to commence in 1H25; Deep and durable responses maintained over 12 months in ...

ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, today announced positive findings from the company’s EMBRACE phase IIb study.

ViiV Healthcare's EMBRACE study shows VH109 with CAB LA effectively suppresses HIV. The company also reports promising early ...

Amkor Technology got a $407 million CHIPS Act grant in December. It comes with strings attached, including commitments to ...

US Bancorp DE cut its position in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Free Report) by 14.0% during the ...

Protagonist Therapeutics, Inc.'s VERIFY and ANTHEM-UC studies show breakthroughs in polycythemia vera and ulcerative colitis.

Trevi Therapeutics, Inc.’s TRVI share price has surged by 41.16%, which has investors questioning if this is right time to sell.